Twenty participants with a BMI of 30 or greater, half on a maintenance dose of GLP-1s and half taking no medication, were recruited from Roanoke and surrounding areas
J Dent 94:103310 Li Z, Li S, Wang N, Xue P, Li Y (2020) Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-kappaB and MAPK pathways via GLP-1R
Studies have demonstrated that both acne vulgaris (AV) and hidradenitis suppurativa (HS) share inflammatory pathways that result in immune system dysregulation through enhanced activity of IL-1, TNF-, and IL-17 pathways leading to follicular occlusion along with neutrophilic inflammation and abnormal keratinocyte proliferation [8]
Regulatory approvals for obesity-specific indications and the shifting perception of obesity as a chronic medical condition rather than a lifestyle issue are further improving market momentum